Beam Therapeutics Inc

BEAM remains in a Stage 4 decline with a confirmed lower-high, lower-low sequence and active Bearish Exhaustion, sustaining a bearish medium-term bias. Price is extended below the declining 9, 21, and 50 EMAs and is extreme oversold, delaying immediate sell entries. Under a speculative framework, sell interactions should be deferred until pullbacks into the EMA or prior support zones for rejection. The long-term uptrend remains intact but faces risk if price breaks below the 200 DMA.

• ↑Beam 101 trial boosted hemoglobin from 9.3 to 17.9 g/dL in early data.
• ↑Q4’25 cash of $1.25B and Sixth Street financing extend runway into 2029.
• ↓Earnings yield at -3.09 and profitability score at -2.49 indicate persistent unprofitability.